Replies to post #12746 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

LD, I am not concerned about share dilution or increased debt. Especially when looking at the combined pro-forma balance sheet (p 38 and 39 of the proxy statement) for 2020. It puts current shareholder in a better position on a per share basis post merger. Revenue growth from the Novitium's 25 ANDAs (sitting on 9 approvals) and Corti and ANI existing ANDA's in the pipe should create additional growth opportunity.

Schedule 14a

Current Assets per share
- Before Merger $14.24
- After Merger $16.12

Total Assets per share
- Before Merger $38.55
- After Merger $47.32


Current liabilities per share
- Before Merger $6.57
- After Merger $4.86

Total liabilities per share
- Before Merger $22.19
- After Merger $27.82

[lawn ranger]

I've been adding to my ANIP shares for the past week or so, picking up some today (7/7) at $33 even. I have much greater confidence in this new CEO getting Corti across the goal line. Also there seems to be a much clearer strategy moving forward following the acquisition of Novitium and the addition of their key upper management to ANIP's roster. I appreciate your posts LD, frequently finding tidbits of wisdom from you.